

Practitioner's Docket No. MPI99-037P1RCP1CN1M

REMARKS

In response to the Restriction Requirement dated February 10, 2005, Applicants hereby elect Group I, drawn to a nucleic acid molecules, vectors, host cells, a method of producing a polypeptide, and a kit comprising a compound which selectively hybridizes to the nucleic acid molecules. Further, Applicants hereby elect encoding a nucleotide sequence encoding a polypeptide comprising the amino acid sequence of SEQ ID NO: 5 (claims 1-7, 12 and 18), with traverse.

Applicant wishes to traverse the Requirement and hereby requests rejoinder of the requirement of election of a single sequence, which includes nucleic acid sequences SEQ ID NO:4, 6, 7, 9, 10, and 12, encoding polypeptide of SEQ ID NO:5, 8, and 11. Applicant submits each of the sequences encode partial or full length human LGR6, and as such, a search of one Group would include a search of other Groups. Thus, joinder of these sequence groups would place no additional burden on the Examiner. In fact, lack of joinder of the Groups would place additional burden on Applicant and the Office in filing and search and exam of additional applications containing overlapping subject matter.

Applicant's election is made without prejudice to Applicant's right to pursue the additional subject matter in other applications. Applicant hereby reserves the right to traverse the above restriction with respect to non-elected Groups II-VIII in this or subsequent applications. Further, Applicant reserves the right to add process claims that depend from or otherwise include all the limitations of elected claims upon indication of allowable claims.

Claims 1-22 have been cancelled and new claims 23-40 have been added. New Claims 23-40 are directed to the subject matter elected, that of original claims 1-7, 12 and 18 (Group I). Support for the new claims lies in elected claims 1-7, 12 and 18 and throughout the specification as filed. No new matter is added by virtue of the amendments made herein.


This paper is being filed timely as a request for a one month extension of time is filed concurrently herewith. It is believed no additional extensions of time are required, however, in the event any additional extensions of time or fees are necessary, the undersigned hereby authorizes the requisite fees to be charged to Deposit Account No. 501668.

Entry of the remarks made herein is respectfully requested.

Respectfully submitted,

April 5, 2005

MILLENNIUM PHARMACEUTICALS, INC.

By 

Kerri Pollard Schray
Registration No. 47,066
40 Lansdowne Street
Cambridge, MA 02139
Telephone - (617) 551-3676
Facsimile - (617) 551-8820

(Page 4 of 4)